Drugs.com: More naloxone orders filled when pharmacists can dispense
UC research on naloxone dispensing makes headlines across the country
Pharmacy researchers at the University of Cincinnati unveiled an impactful research study on Jan. 31, 2020 that shows an association between a 2015 Ohio law and a surge in the dispensing of naloxone in Ohio pharmacies. Naloxone is the anti-overdose drug and pharmacists here can now legally dispense it in the state, without a prescription.
While the study focused solely on the increase in distribution of this lifesaving medication, the implications are that death rates by overdose drop up to 14% in states where access is increased. As the opioid crisis continues to plague the U.S. and other countries, reporters from national, regional and local outlets took great interest in the study. The college dean, Neil MacKinnon, and lead faculty researcher, Pamela Heaton, participated in both televsion and print media interviews within days of the study's release.
A sample of the widespread interest includes:
- USA Today: News from around our 50 states
- Drugs.com: More Naloxone Orders Filled When Pharmacists Can Dispense
- U.S. News and World Report: Study: Naloxone Dispensing Increased More Than 2,000%
- AP: Study: Naloxone dispensing increased more than 2,000%
- UPI: Naloxone sales up 2,300% in Ohio after law loosens pharmacist restrictions
- WBNS: Study: Naloxone dispensing in Ohio increased more than 2,000% since 2015
Featured image: generic pharmacy purchases/unsplash.com/Tbel Abuseridze
Related Stories
UC Board of Trustees approves $12 million for building design phase for new welcome gateway
March 13, 2026
The UC Board of Trustees approved $12 million at its Feb. 24 meeting for the design phase of a new Welcome Gateway Building for Uptown campus.
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.